Margetuximab
Showing 1 - 7 of 7
Metastatic Breast Cancer, Advanced Breast Cancer, HER2-positive Breast Cancer Trial (Margetuximab, Tucatinib, Capecitabine)
Withdrawn
- Metastatic Breast Cancer
- +2 more
- Margetuximab
- +2 more
- (no location specified)
Jul 6, 2022
HER2-positive Breast Cancer, HER2-positive Carcinoma Trial (Margetuximab)
Approved for marketing
- HER2-positive Breast Cancer
- HER2-positive Carcinoma
- Margetuximab
- (no location specified)
Feb 21, 2022
HER2 Positive Metastatic Breast Cancer Trial in Beijing, Shijiazhuang, Zhengzhou (Margetuximab Margetuximab-IV)
Completed
- HER2 Positive Metastatic Breast Cancer
- Margetuximab Margetuximab-IV
-
Beijing, Beijing, China
- +2 more
Jun 11, 2021
Gastric Cancer, Gastroesophageal Junction Cancer, HER2-positive Gastric Cancer Trial in Worldwide (margetuximab, Retifanlimab,
Active, not recruiting
- Gastric Cancer
- +2 more
- margetuximab
- +4 more
-
Scottsdale, Arizona
- +72 more
Aug 24, 2022
Breast Cancer Metastatic Trial in Taipei (Margetuximab, Trastuzumab, Chosen Chemotherapy (Capecitabine))
Unknown status
- Breast Cancer Metastatic
- Margetuximab
- +4 more
-
Taipei, TaiwanNational Taiwan University Hospital
Feb 6, 2020
HER-2 Positive Breast Cancer, Metastatic Tumor Trial in Worldwide (Margetuximab, Trastuzumab, Capecitabine)
Active, not recruiting
- HER-2 Positive Breast Cancer
- Metastatic Neoplasm
- Margetuximab
- +5 more
-
Chandler, Arizona
- +166 more
Oct 18, 2021